Archvest Wealth Advisors Inc. Purchases New Shares in Amgen Inc. $AMGN

Archvest Wealth Advisors Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 3,801 shares of the medical research company’s stock, valued at approximately $1,190,000. Amgen accounts for about 0.3% of Archvest Wealth Advisors Inc.’s holdings, making the stock its 25th biggest holding.

Other hedge funds have also bought and sold shares of the company. Dogwood Wealth Management LLC raised its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC boosted its stake in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the 4th quarter worth about $26,000. Manning & Napier Advisors LLC grew its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC purchased a new stake in Amgen in the 4th quarter worth about $33,000. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is owned by insiders.

Amgen Trading Up 3.0%

Shares of AMGN opened at $338.22 on Thursday. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a 50-day moving average of $341.49 and a 200 day moving average of $345.38. The firm has a market capitalization of $182.54 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 3.29 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen secured European Commission approval for Imdylltra in a lung cancer indication, strengthening the drug’s commercial outlook and validating its clinical profile. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen also announced new data presentations at the EULAR 2026 conference for rare autoimmune and inflammatory diseases, including longer-term safety and efficacy data for UPLIZNA and TAVNEOS, which may support these products’ market positioning. AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
• Positive Sentiment: Another report highlighted analyst commentary on Amgen, which can reinforce investor confidence if recent updates are viewed favorably by the market. Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
• Neutral Sentiment: A feature story noted Amgen’s early adoption of AI under CEO Bob Bradway, underscoring the company’s push to improve research productivity, though it is not an immediate financial catalyst. The CEO who loves AI autodidacts — and desperately needs his experts

Analyst Upgrades and Downgrades

AMGN has been the subject of several analyst reports. Argus decreased their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Finally, Barclays initiated coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $355.19.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.